

PDX Data Sheet for COG-N-496x

Disease: Neuroblastoma
Phase of Therapy: Diagnosis
Treatment: None
Disease Stage: 4
Gender: Female
Age at diagnosis: 38.4 months
Race: NA
Age at sample collection: 38.4 months
Source of culture: Bone marrow November 2013
Primary tumor site: NA
Date Established: January 2013

MYCN Patient: Amplified
MYCN PDX: Relative copy number – 48 copies
TH mRNA: Expressed
p53 functionality: NA
Telomere Mechanism: TERT+++ , C-circle negative
ALK: Wild Type

PDX RNAseq: Available upon request
PDX WES: Available upon request
Strain of Mice: NSG or Athymic NuNu (recommended)
Injection Type: Subcutaneous
Growth Properties: 10e6 cells injected in Athymic NuNu, 1 months to 1500mm³
Please see Protocols section at
<https://www.cccells.org/protocols.php>

Human vs. Mouse: This PDX model has been tested and confirmed over multiple passages to be above 90% human cells.

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes: The Childhood Cancer Repository has a matching direct-to-culture cell line available from this same patient – COG-N-496. The Childhood Cancer Repository has a matching hypoxic cell line grown at 5% O₂ and 2% O₂ available from this same patient – COG-N-496h and COG-N-496h2.

h-IMPACT Profile I IDEXX: PCR evaluation of EBV, HAdV, Hantaan, HCMV, Hepatitis A, Hepatitis B, Hepatitis C, HHV 6, HHV8, HIV1, HIV2, HSV 1, HSV 2, HTLV 1, HTLV2, LCMV, Mycoplasma sp., Seoul, Sin Nombre, VZV were all negative.



PDX Data Sheet for COG-N-496x

Cell Line Name: COG-N-496x

References:

1. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. *Sci Data*. 2017;4:170033. PMID: 28350380
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369315/>



PDX Data Sheet for COG-N-496x

PDX Name: COG-N-496x

H&E slides